A novel platform for biologically active recombinant human interleukin-13 production

Area of Science:

• Biotechnology
• Molecular Biology
• Immunology

Background:

• Interleukin-13 (IL-13) is a key cytokine for treating diseases like type-1 diabetes.
• Conventional methods for producing recombinant IL-13 are inefficient.
• Transgenic plants offer a novel platform for protein production.

Purpose of the Study:

• To develop transgenic tobacco plants for efficient production of human IL-13 (hIL-13).
• To characterize the properties and biological activity of plant-derived rhIL-13.
• To evaluate transgenic plants as a superior expression system for rhIL-13.

Main Methods:

• Genetic engineering of tobacco plants with hIL-13 cDNA.
• Confirmation of gene expression using RT-PCR and Northern blotting.
• Protein analysis via Western blotting, deglycosylation, and in vitro digestion assays.
• Biological activity assessment using TF-1 cell line bioassays.

Main Results:

• Transgenic plants accumulated high levels of rhIL-13 (0.15% of total soluble protein).
• Plant-derived rhIL-13 exhibited differential N-linked glycosylation and increased resistance to proteolysis.
• Plant-derived rhIL-13 retained biological function in vitro.
• Transgenic plants demonstrated superior expression compared to conventional systems.

Conclusions:

• Transgenic plants are an effective and efficient platform for producing functional recombinant human IL-13.
• Plant-derived rhIL-13 shows enhanced stability and retains therapeutic potential.
• This system may enable oral administration of IL-13 for treating diseases like type-1 diabetes.